Gilead(US:GILD) Di Yi Cai Jing·2025-06-19 02:20Group 1: Core Insights - The FDA has approved Gilead's Yeztugo (lenacapavir), the first HIV prevention drug that requires administration only twice a year [1] - Clinical trials (PURPOSE 1 and PURPOSE 2) showed that ≥99.9% of participants maintained an HIV-negative status after treatment [1] - The drug demonstrated a 100% reduction in HIV infection rates among cisgender women and a 99.9% reduction among men who have sex with men, transgender men, transgender women, and non-binary individuals [1] Group 2: Mechanism and Approval Status - Lenacapavir is a novel long-acting HIV capsid inhibitor that binds directly to HIV capsid protein subunits, disrupting multiple key steps in the virus lifecycle [2] - Prior to this approval, lenacapavir had not been authorized for pre-exposure prophylaxis in other countries, although it has been approved for treating multi-drug resistant HIV in the EU and the US [2] - The drug has not yet been approved for use in China [2] Group 3: Public Health Implications - HIV remains a significant global public health issue, and while developing preventive vaccines is challenging, HIV is increasingly seen as a manageable chronic disease [3] - The introduction of a biannual injection could improve adherence among high-risk populations who struggle with daily medication regimens [3] - If widely adopted, this treatment could further reduce the prevalence of HIV [3]